- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00537745
Vivitrol for Reducing Driving While Impaired Behavior Among Repeat Offenders
August 23, 2012 updated by: Sandra Lapham, Pacific Institute for Research and Evaluation
Vivitrol for Reducing Driving While Impaired Behavior Among Repeat Offenders-a Pilot Study
The purpose of this study is to determine whether Vivitrol is effective at reducing attempts to drive after drinking among repeat driving while intoxicated (DWI) offenders with Ignition Interlock devices.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
We propose to conduct an open label trial of Vivitrol in combination with an individual compliance enhancement therapy known as Medication Management Therapy (MMT) as an adjunct to Ignition Interlock in the management and treatment of DWI.
Subjects will be recruited from a local Interlock provider.
This program of research will collect pilot data for a study to determine whether pharmacotherapy, previously recognized as effective, can be successfully combined with existing counseling treatments and sanctions for persons convicted of a repeat DWI alcohol offense.
We will investigate the extent to which this combination of sanctions and treatment will significantly decrease attempts to drive after drinking among offenders, and whether the effect persists following discontinuation of Vivitrol.
Study Type
Interventional
Enrollment (Actual)
14
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87102
- Behavioral Health Research Center of the Southwest
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria
- Age ≥ 18
- Capable of understanding and complying with the protocol, and has signed the informed consent document
- Been convicted of a DWI offense, have at least one additional arrest for DWI, and be entering an ignition interlock program
- They must be able to participate in a 6 month outpatient study; and reside within a one-hour commute to the research site
- Women of childbearing potential must have a negative pregnancy test, use contraceptive methods, and not be breastfeeding
- Negative urine toxicological screen for opiates at screening and randomization
- Has a non-custodial stable residence and telephone
Exclusion Criteria
- Is pregnant and/or currently breastfeeding
- Has a clinically significant medical condition or observed abnormality that is contraindicated for Vivitrol treatment
- Is taking an excluded medication, including but not limited to benzodiazepines, anticonvulsants, opiates, or alcohol treatment medication
- Not stable on current anti-depressant, as evidenced by less than 3 months at current dosage, plans to discontinue, or plans to change the dosage
- Has been hospitalized for medical detoxification within 30 days of screening
- Has evidence of severe kidney, heart, or lung disease
- Has evidence of severe hepatic disease (as evidence by BUN > 10% above ULN, AST, ALT > 3x ULN, and GGT > 5x ULN at randomization)
- Known or suspected hypersensitivity to naltrexone and/or Vivitrol in particular
- Current diagnosis and symptoms of major depression, anxiety disorder, mania or psychosis (subjects with their illness in remission for 3 months may be included)
- Opioid use within the past 14 days and/or current or recent (within the past year) diagnosis of dependence or abuse of opiates, benzodiazepines, or cocaine.
- Current or anticipated need for prescribed opiate medication during the study period
- Medication with naltrexone, disulfiram, acamprosate or other medication used to treat alcoholism within the past 30 days
- Impending incarceration or other known situation that would preclude participation in the study
- Other non-alcohol Axis I substance dependence diagnosis in the past 12 months, excluding nicotine, marijuana, and caffeine
- Has participated in a clinical trial of a pharmacological agent within 30 days of screening
- Has any finding that in the view of the principal investigator would compromise the subject's ability to fulfill the protocol visit schedule, and/or visit requirements or would affect subject safety during participation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vivitrol
Vivitrol 380 mg/monthly, plus individual compliance enhancement therapy (Medication Management Therapy).
|
Vivitrol 380 mg/monthly
Medication Management Therapy once a month.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evidence of Attempts to Drive After Drinking
Time Frame: 6 months
|
This was measured as Percent of days with an Interlock report of "Failure to Start" due to alcohol pre/on medication and 6 months post medication.
|
6 months
|
% Days w/1+Interlock Test Failures
Time Frame: One month post treatment
|
This describes the percent of days in past month where the subject at least 1 interlock test failure.
|
One month post treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Sandra Lapham, MD, MPH, Pacific Institute for Research and Evaluation
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2007
Primary Completion (Actual)
May 1, 2009
Study Completion (Actual)
May 1, 2009
Study Registration Dates
First Submitted
September 28, 2007
First Submitted That Met QC Criteria
September 30, 2007
First Posted (Estimate)
October 1, 2007
Study Record Updates
Last Update Posted (Estimate)
August 27, 2012
Last Update Submitted That Met QC Criteria
August 23, 2012
Last Verified
August 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C18816/6075/DP/US
- 0328.01.01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcohol Consumption
-
Centre for Addiction and Mental HealthCanadian Institutes of Health Research (CIHR)CompletedAlcohol Consumption | Hazardous Alcohol ConsumptionCanada
-
Centre for Addiction and Mental HealthUniversity of HoustonCompleted
-
Wayne State UniversityCompleted
-
Institut national de prevention et d'education...CompletedHazardous Alcohol Consumption
-
International Agency for Research on CancerUniversidad de Murcia; Federico II University; University of Tromso; Imperial College... and other collaboratorsCompletedNo Condition, Focus: Metabolites of Alcohol Consumption
-
Denver Health and Hospital AuthorityMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.CompletedModerate Alcohol Consumption (1-3 Drinks Per Day)
-
Jordi Gol i Gurina FoundationSocietat Catalana de Medicina Familiar i Comunitària (CAMFIC); Associació Catalana... and other collaboratorsUnknownAlcohol Consumption | Traffic Accident | Risk Perception of Driving After Alcohol ConsumptionSpain
-
University of WashingtonNational Institutes of Health (NIH); National Institute on Aging (NIA); Seattle...Active, not recruitingMild to Heavy Alcohol ConsumptionUnited States
-
Technische Universität DresdenCharite University, Berlin, GermanyCompletedHigh-risk Alcohol Consumption Pattern | Low-risk Alcohol Consumption PatternGermany
-
Brown UniversityCompletedPhysical Activity | Stress, Psychological | Sleep | Loneliness | Diet Habit | Emotional Regulation | Alcohol Consumption, YouthUnited States
Clinical Trials on Vivitrol (Medication Therapy)
-
University of Illinois at ChicagoDuke University; Baylor Research Institute; RTI International; Agency for Healthcare...CompletedElderly Patients | Chronic Illness | Adverse Effects | Medication ErrorsUnited States
-
Tabula Rasa HealthCareCompletedPharmacogenomics | Medication Therapy ManagementUnited States
-
University of North Texas Health Science CenterUniversity of California, San Francisco; University of Minnesota; Walgreens,...Active, not recruitingHypertension | Diabetes Mellitus, Type 2 | HIV/AIDSUnited States
-
Daniela MogaNational Institute on Aging (NIA); Northern California Institute of Research...TerminatedDementia | Mild Cognitive ImpairmentUnited States
-
Ohio State UniversityWithdrawnMedication Therapy Management | Medication Management | Estimated Cost Avoidance | MTM
-
University Hospital, ToulouseCompletedMedication Therapy ManagementFrance
-
University Hospital, ToulouseInstitut National de la Santé Et de la Recherche Médicale, FranceCompletedMedication Therapy ManagementFrance
-
Yale UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedReduction in Heavy Drinking in Patients With HIVUnited States
-
The Hong Kong Polytechnic UniversityCastle Peak Hospital; Kwai Chung Hospital, Hong KongCompletedSchizophrenia | Schizoaffective Disorder | Schizophreniform DisorderHong Kong
-
Merit UniversityNot yet recruiting